Home » Stocks » LivaNova

LivaNova PLC (LIVN)

Stock Price: $52.39 USD -0.15 (-0.29%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 2.55B
Revenue (ttm) 980.80M
Net Income (ttm) -161.52M
Shares Out 48.67M
EPS (ttm) -3.33
PE Ratio n/a
Forward PE 31.65
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $52.39
Previous Close $52.54
Change ($) -0.15
Change (%) -0.29%
Day's Open 52.38
Day's Range 51.49 - 52.97
Day's Volume 242,684
52-Week Range 33.40 - 85.30

More Stats

Market Cap 2.55B
Enterprise Value 3.01B
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 48.67M
Float 48.42M
EPS (basic) -3.33
EPS (diluted) -3.33
FCF / Share -4.75
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.53M
Short Ratio 5.71
Short % of Float 5.23%
Beta 0.85
PE Ratio n/a
Forward PE 31.65
P/FCF Ratio n/a
PS Ratio 2.60
PB Ratio 1.98
Revenue 980.80M
Operating Income -132.84M
Net Income -161.52M
Free Cash Flow -230.64M
Net Cash -456.48M
Net Cash / Share -9.38
Gross Margin 74.59%
Operating Margin -13.54%
Profit Margin -16.50%
FCF Margin -23.51%
ROA -1.08%
ROE -11.41%
ROIC -15.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (8)

Buy 5
Overweight 2
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(24.07% upside)
Current: $52.39
Target: 65.00
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-2.06%9.35%4.91%230.93%3.38%10.89%-62.63%-
Gross Profit745734652559264255232371
Operating Income-169-23712733.4588.6580.0178.3533.22
Net Income-155-189-25.09-62.7957.8554.8946.3618.24
Shares Outstanding48.3548.5048.1648.8626.3927.1427.60-
Earnings Per Share-3.21-3.91-0.52-
EPS Growth----8.5%20.48%4511.11%-
Operating Cash Flow-91.1412091.3490.1579.6854.2079.0571.59
Capital Expenditures-24.69-37.19-32.93-38.36-6.69-15.22-9.71-19.97
Free Cash Flow-11683.3058.4151.7972.9938.9769.3551.61
Cash & Equivalents61.1447.2093.6239.79151128--
Total Debt384168146123----
Net Cash / Debt-323-121-52.38-83.08151128--
Book Value1,3841,5041,8151,707277259--
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name LivaNova PLC
Country United Kingdom
Employees 4,000
CEO Damien McDonald

Stock Information

Ticker Symbol LIVN
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Unique Identifier NASDAQ: LIVN
IPO Date February 10, 1993


LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV?) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, treatment-resistant depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. LivaNova PLC has a research collaboration with Verily to gain insights into Vagus nerve stimulation impact on difficult-to-treat depression. The company was founded in 1987 and is headquartered in London, the United Kingdom.